FDA declines to approve Daiichi Sankyo's blood cancer treatment

FDA declines to approve Daiichi Sankyo's blood cancer treatment

Source: 
Reuters
snippet: 

Japan’s Daiichi Sankyo Co said on Friday the U.S. Food and Drug Administration has declined to approve its drug quizartinib as a treatment for adults with a type of blood cancer.